IP Library Granted Patent US 10,385,008
Granted Patent B2
US 10,385,008 · App. 15/863,850 · Granted Aug 20, 2019

Polymorphic forms of RAD1901-2HCL

Inventors: Michael Paul Cruskie, Jr. (Florence, SC); Joshua Kyle Bolger (Florence, SC); Jonathan Blake McKenzie (Latta, SC); Pratik Sheth (Waltham, MA); Richard Edwards (Cambridge, GB); Alex Eberlin (Cambridge, GB); Michael Markey (Waltham, MA)
Assignee: Radius Pharmaceuticals, Inc.
C07C217/84A61P35/00C07C213/10C07B2200/13
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,385,008
App. No.
15/863,850
Granted
Aug 20, 2019
Kind
B2
Abstract

Various polymorphic forms of RAD1901-2HCl, including three crystalline and amorphous forms, are prepared and characterized. Uses of the various polymorphic forms of RAD1901-2HCl for cancer treatment are also disclosed.

Claims (18)

1. A solid form of RAD1901-2HCl, having an X-ray powder diffraction pattern comprising a peak, in terms of 2-theta, at 7.1 degrees 2θ±0.2 degree 2θ at about relative humidity 0%.

2. The solid form of claim 1 , having an X-ray powder diffraction pattern comprising peaks, in terms of 2-theta, at 7.1 degrees 2θ±0.2 degree 2θ and 14.3 degrees 2θ±0.2 degree 2θ at about relative humidity 0%.

3. The solid form of claim 1 , having an X-ray powder diffraction pattern further comprising at least one peak, in terms of 2-theta, selected from the group consisting of 14.3 degrees 2θ±0.2 degree 2θ and 18.3 degrees 2θ±0.2 degree 2θ at about relative humidity 0%.

4. The solid form of claim 1 , having an X-ray powder diffraction pattern further comprising at least two peaks, in terms of 2-theta, selected from the group consisting of 14.3 degrees 2θ±0.2 degree 2θ, 18.3 degrees 2θ±0.2 degree 2θ, 13.8 degrees 2θ±0.2 degree 2θ and 12.0 degrees 2θ±0.2 degree 2θ, at about relative humidity 0%.

5. The solid form of claim 1 , having an X-ray powder diffraction pattern further comprising at least three peaks, in terms of 2-theta, selected from the group consisting of 14.3 degrees 2θ±0.2 degree 2θ, 18.3 degrees 2θ±0.2 degree 2θ, 13.8 degrees 2θ±0.2 degree 2θ, 12.0 degrees 2θ±0.2 degree 2θ, 25.1 degrees 2θ±0.2 degree 2θ and 18.9 degrees 2θ±0.2 degree 2θ, at about relative humidity 0%.

6. The solid form of claim 1 , having an X-ray powder diffraction pattern further comprising at least four peaks, in terms of 2-theta, selected from the group consisting of 14.3 degrees 2θ±0.2 degree 2θ, 18.3 degrees 2θ±0.2 degree 2θ, 13.8 degrees 2θ±0.2 degree 2θ, 12.0 degrees 2θ±0.2 degree 2θ, 25.1 degrees 2θ±0.2 degree 2θ, 18.9 degrees 2θ±0.2 degree 2θ, 27.2 degrees 2θ±0.2 degree 2θ and 11.0 degrees 2θ±0.2 degree 2θ, at about relative humidity 0%.

7. The solid form of claim 1 , having an X-ray powder diffraction pattern further comprising at least four peaks, in terms of 2-theta, selected from the group consisting of 14.3 degrees 2θ±0.2 degree 2θ, 18.3 degrees 2θ±0.2 degree 2θ, 13.8 degrees 2θ±0.2 degree 2θ, 12.0 degrees 2θ±0.2 degree 2θ, 25.1 degrees 2θ±0.2 degree 2θ, 18.9 degrees 2θ±0.2 degree 2θ, 27.2 degrees 2θ±0.2 degree 2θ, 11.0 degrees 2θ±0.2 degree 2θ and 16.2 degrees 2θ±0.2 degree 2θ, at about relative humidity 0%.

8. The solid form of claim 1 , having an X-ray powder diffraction pattern further comprising at least six peaks, in terms of 2-theta, selected from the group consisting of 14.3 degrees 2θ±0.2 degree 2θ, 18.3 degrees 2θ±0.2 degree 2θ, 13.8 degrees 2θ±0.2 degree 2θ, 12.0 degrees 2θ±0.2 degree 2θ, 25.1 degrees 2θ±0.2 degree 2θ, 18.9 degrees 2θ±0.2 degree 2θ, 27.2 degrees 2θ±0.2 degree 2θ, 11.0 degrees 2θ±0.2 degree 2θ and 16.2 degrees 2θ±0.2 degree 2θ, at about relative humidity 0%.

9. The solid form of claim 1 , having an X-ray powder diffraction pattern further comprising at least seven peaks, in terms of 2-theta, selected from the group consisting of 14.3 degrees 2θ±0.2 degree 2θ, 18.3 degrees 2θ±0.2 degree 2θ, 13.8 degrees 2θ±0.2 degree 2θ, 12.0 degrees 2θ±0.2 degree 2θ, 25.1 degrees 2θ±0.2 degree 2θ, 18.9 degrees 2θ±0.2 degree 2θ, 27.2 degrees 2θ±0.2 degree 2θ, 11.0 degrees 2θ±0.2 degree 2θ and 16.2 degrees 2θ±0.2 degree 2θ, at about relative humidity 0%.

10. The solid form of claim 1 , having an X-ray powder diffraction pattern further comprising at least eight peaks, in terms of 2-theta, selected from the group consisting of 14.3 degrees 2θ±0.2 degree 2θ, 18.3 degrees 2θ±0.2 degree 2θ, 13.8 degrees 2θ±0.2 degree 2θ, 12.0 degrees 2θ±0.2 degree 2θ, 25.1 degrees 2θ±0.2 degree 2θ, 18.9 degrees 2θ±0.2 degree 2θ, 27.2 degrees 2θ±0.2 degree 2θ, 11.0 degrees 2θ±0.2 degree 2θ and 16.2 degrees 2θ±0.2 degree 2θ, at about relative humidity 0%.

11. The solid form of claim 1 , having an X-ray powder diffraction pattern comprising the peaks, in terms of 2-theta, of 7.1 degrees 2θ±0.2 degree 2θ, 14.3 degrees 2θ±0.2 degree 2θ, 18.3 degrees 2θ±0.2 degree 2θ, 13.8 degrees 2θ±0.2 degree 2θ, 12.0 degrees 2θ±0.2 degree 2θ, 25.1 degrees 2θ±0.2 degree 2θ, 18.9 degrees 2θ±0.2 degree 2θ, 27.2 degrees 2θ±0.2 degree 2θ, 11.0 degrees 2θ±0.2 degree 2θ and 16.2 degrees 2θ±0.2 degree 2θ, at about relative humidity 0%.

12. The solid form of claim 1 , having an X-ray powder diffraction pattern as shown in FIG. 4G at about relative humidity 0%.

13. A solid form of RAD1901-2HCl, having a differential scanning calorimetry (DSC) thermogram comprising a melting onset at 218.2° C. and an endothermic peak at 232.1° C.

14. The solid form of claim 13 , having a differential scanning calorimetry (DSC) thermogram as shown in the bottom figure of FIG. 8 .

15. A solid form of RAD1901-2HCl, having a thermogravimetric analysis (TGA) as shown in the top graph of FIG. 8 .

16. A pharmaceutical composition comprising the solid form of claim 1 and one or more pharmaceutically acceptable excipients.

17. A process for preparing the solid form of claim 1 comprising precipitating from a solution comprising RAD1901-2HCl and a solvent, or slurrying RAD1901-2HCl in a solvent, wherein the solvent comprises an organic solvent excluding methanol, and the content of water is at or below 5% v/v.

18. The process according to claim 17 wherein the organic solvent is selected from the group consisting of n-heptane, propyl acetate, ethyl acetate, isopropyl acetate, methyl isobutyl ketone (MIBK), methyl ethyl ketone (MEK), 1-propanol, ethanol, t-butyl methyl ether (TBME), 1,4-dioxane, toluene, 1,2-dimethoxyethane, tetrahydrofuran, dichloromethane, acetonitrile, nitromethane, and mixtures thereof.

Assignments (11)
RELEASE OF SECURITY INTEREST Recorded Oct 30, 2025
From: WILMINGTON TRUST, NATIONAL ASSOCIATION
To: RADIUS HEALTH, INC.
Reel/Frame 073278/0396 →
SECURITY INTEREST Recorded Aug 16, 2022
From: RADIUS HEALTH, INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION
Reel/Frame 061179/0001 →
RELEASE OF SECURITY INTEREST Recorded Aug 15, 2022
From: MIDCAP FUNDING IV TRUST
To: RADIUS HEALTH, INC.; RADIUS PHARMACEUTICALS, INC.
Reel/Frame 061176/0914 →
RELEASE OF SECURITY INTEREST Recorded Aug 15, 2022
From: MIDCAP FINANCIAL TRUST
To: RADIUS HEALTH, INC.; RADIUS PHARMACEUTICALS, INC.
Reel/Frame 061176/0938 →
REAFFIRMATION, JOINDER & AMENDMENT TO SECURITY AGREEMENT (TERM) Recorded Mar 17, 2021
From: RADIUS HEALTH, INC.; RADIUS PHARMACEUTICALS, INC.; RADIUS HEALTH VENTURES, INC.
To: MIDCAP FINANCIAL TRUST, AS AGENT
Reel/Frame 055632/0017 →
REAFFIRMATION, JOINDER & AMENDMENT TO SECURITY AGREEMENT (REVOLVING) Recorded Mar 17, 2021
From: RADIUS HEALTH, INC.; RADIUS PHARMACEUTICALS, INC.; RADIUS HEALTH VENTURES, INC.
To: MIDCAP FUNDING IV TRUST, AS AGENT
Reel/Frame 055632/0316 →
RELEASE OF SECURITY INTEREST Recorded Jul 27, 2020
From: MIDCAP FINANCIAL TRUST; MIDCAP FUNDING IV TRUST
To: RADIUS PHARMACEUTICALS, INC.; RADIUS HEALTH, INC.
Reel/Frame 053315/0231 →
ASSIGNMENT OF INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Jul 6, 2020
From: MIDCAP FINANCIAL TRUST
To: MIDCAP FUNDING IV TRUST
Reel/Frame 053131/0465 →
SECURITY INTEREST (REVOLVING) Recorded Jan 15, 2020
From: RADIUS HEALTH, INC.; RADIUS PHARMACEUTICALS, INC.
To: MIDCAP FINANCIAL TRUST, AS AGENT
Reel/Frame 051618/0758 →
SECURITY INTEREST (TERM) Recorded Jan 15, 2020
From: RADIUS HEALTH, INC.; RADIUS PHARMACEUTICALS, INC.
To: MIDCAP FINANCIAL TRUST, AS AGENT
Reel/Frame 051618/0200 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 8, 2019
From: CRUSKIE, MICHAEL PAUL; BOLGER, JOSHUA KYLE; MCKENZIE, JONATHAN BLAKE; SHETH, PRATIK; EDWARDS, RICHARD; EBERLIN, ALEX; MARKEY, MICHAEL
To: RADIUS PHARMACEUTICALS, INC.
Reel/Frame 048275/0709 →
Continuity (2)
Provisional Application 62442921 · Jan 5, 2017
Related Publication 20180186726A1 · Jul 5, 2018
Cited By (1)
US 12,398,094